Skip to main content

Alcohol Withdrawal

2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
1
KetaminePhase 41 trial
Patient navigationN/A1 trial
Active Trials
NCT03737864Completed206Est. Nov 2024
NCT02823977Withdrawn0Est. Dec 2018
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
RiboflavinPhase 21 trial
Active Trials
NCT04232800Unknown40Est. Oct 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Colorado TherapeuticsKetamine
Oregon TherapeuticsRiboflavin
Colorado TherapeuticsPatient navigation

Clinical Trials (3)

Total enrollment: 246 patients across 3 trials

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

Start: Feb 2018Est. completion: Dec 20180
Phase 4Withdrawn

Riboflavin for Glutamate Reduction in Alcohol Withdrawal

Start: Dec 2021Est. completion: Oct 202240 patients
Phase 2Unknown

NCARE, Transition to Recovery

Start: Jun 2019Est. completion: Nov 2024206 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.